RYTM Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -82.97% compared to Rhythm Pharmaceuticals, Inc.'s net margin of -64.86%. Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34% beat Geron Corp.'s return on equity of -33.44%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $139.67, signalling upside risk potential of 53.48%. On the other hand Geron Corp. has an analysts' consensus of $3.40 which suggests that it could grow by 131.29%. Given that Geron Corp. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Geron Corp. is more attractive than Rhythm Pharmaceuticals, Inc..

Rhythm Pharmaceuticals, Inc. has a beta of 2.058, which suggesting that the stock is 105.795% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.581, suggesting its less volatile than the S&P 500 by 41.892%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $57.3M, which are larger than Geron Corp. quarterly revenues of $48M. Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M is lower than Geron Corp.'s net income of -$31.1M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 31.16x versus 5.33x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -82.97% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 20.83%. Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34% beat Johnson & Johnson's return on equity of 34.46%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $139.67, signalling upside risk potential of 53.48%. On the other hand Johnson & Johnson has an analysts' consensus of $233.13 which suggests that it could fall by -4.96%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Rhythm Pharmaceuticals, Inc. has a beta of 2.058, which suggesting that the stock is 105.795% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.12% to investors and pays a quarterly dividend of $1.30 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $57.3M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M is lower than Johnson & Johnson's net income of $5.1B. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 22.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 31.16x versus 6.32x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -82.97% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 34.4%. Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34% beat Eli Lilly & Co.'s return on equity of 104.39%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $139.67, signalling upside risk potential of 53.48%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 21%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Rhythm Pharmaceuticals, Inc. has a beta of 2.058, which suggesting that the stock is 105.795% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $57.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 44.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 31.16x versus 14.03x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

MannKind Corp. has a net margin of -82.97% compared to Rhythm Pharmaceuticals, Inc.'s net margin of -14.25%. Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34% beat MannKind Corp.'s return on equity of --.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $139.67, signalling upside risk potential of 53.48%. On the other hand MannKind Corp. has an analysts' consensus of $7.72 which suggests that it could grow by 161.77%. Given that MannKind Corp. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe MannKind Corp. is more attractive than Rhythm Pharmaceuticals, Inc..

Rhythm Pharmaceuticals, Inc. has a beta of 2.058, which suggesting that the stock is 105.795% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.834, suggesting its less volatile than the S&P 500 by 16.605%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $57.3M, which are smaller than MannKind Corp. quarterly revenues of $112M. Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M is lower than MannKind Corp.'s net income of -$15.9M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 175.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 31.16x versus 2.64x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.